# C_2023087EN.01001401.xml

| 9.3.2023 | EN | Official Journal of the European Union | C 87/14 |
| --- | --- | --- | --- |

9.3.2023

EN

Official Journal of the European Union

C 87/14

---

Medicinal Products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2022

(2023/C 87/08)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2022, at their meeting on 28 October 2022:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

| Annex V | List of suspended marketing authorisations |
| --- | --- |

Annex V

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2022:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/21/1540 | Dasatinib Accord | Norway | 7.4.2022 |
| EU/1/21/1540 | Dasatinib Accord | Iceland | 8.4.2022 |
| EU/1/21/1540 | Dasatinib Accord | Liechtenstein | 31.3.2022 |
| EU/1/21/1541 | Dasatinib Accordpharma | Norway | 7.4.2022 |
| EU/1/21/1541 | Dasatinib Accordpharma | Iceland | 8.4.2022 |
| EU/1/21/1541 | Dasatinib Accordpharma | Liechtenstein | 31.3.2022 |
| EU/1/21/1569 | QINLOCK | Norway | 11.1.2022 |
| EU/1/21/1578 | Ontilyv | Norway | 25.2.2022 |
| EU/1/21/1578 | Ontilyv | Iceland | 24.2.2022 |
| EU/1/21/1578 | Ontilyv | Liechtenstein | 28.2.2022 |
| EU/1/21/1579 | Nexviadyme | Liechtenstein | 30.6.2022 |
| EU/1/21/1586 | Voraxaze | Norway | 24.1.2022 |
| EU/1/21/1586 | Voraxaze | Iceland | 10.2.2022 |
| EU/1/21/1586 | Voraxaze | Liechtenstein | 31.1.2022 |
| EU/1/21/1596 | Tepmetko | Norway | 22.2.2022 |
| EU/1/21/1596 | Tepmetko | Iceland | 22.2.2022 |
| EU/1/21/1596 | Tepmetko | Liechtenstein | 28.2.2022 |
| EU/1/21/1598 | Sitagliptin SUN | Norway | 3.1.2022 |
| EU/1/21/1599 | Vyepti | Norway | 7.2.2022 |
| EU/1/21/1599 | Vyepti | Iceland | 28.1.2022 |
| EU/1/21/1599 | Vyepti | Liechtenstein | 31.1.2022 |
| EU/1/21/1600 | Tecovirimat SIGA | Norway | 17.1.2022 |
| EU/1/21/1600 | Tecovirimat SIGA | Iceland | 14.1.2022 |
| EU/1/21/1600 | Tecovirimat SIGA | Liechtenstein | 31.1.2022 |
| EU/1/21/1602 | Uplizna | Norway | 16.5.2022 |
| EU/1/21/1602 | Uplizna | Iceland | 13.5.2022 |
| EU/1/21/1602 | Uplizna | Liechtenstein | 30.4.2022 |
| EU/1/21/1603 | Lumykras | Norway | 11.1.2022 |
| EU/1/21/1603 | Lumykras | Iceland | 25.1.2022 |
| EU/1/21/1603 | Lumykras | Liechtenstein | 31.1.2022 |
| EU/1/21/1604 | Riltrava Aerosphere | Norway | 11.1.2022 |
| EU/1/21/1604 | Riltrava Aerosphere | Iceland | 19.1.2022 |
| EU/1/21/1604 | Riltrava Aerosphere | Liechtenstein | 31.1.2022 |
| EU/1/21/1605 | Tavneos | Norway | 19.1.2022 |
| EU/1/21/1605 | Tavneos | Iceland | 14.2.2022 |
| EU/1/21/1605 | Tavneos | Liechtenstein | 31.1.2022 |
| EU/1/21/1606 | Yselty | Norway | 22.6.2022 |
| EU/1/21/1606 | Yselty | Iceland | 21.6.2022 |
| EU/1/21/1606 | Yselty | Liechtenstein | 30.6.2022 |
| EU/1/21/1607 | Lonapegsomatropin Ascendis Pharma | Norway | 21.1.2022 |
| EU/1/21/1607 | Lonapegsomatropin Ascendis Pharma | Iceland | 1.2.2022 |
| EU/1/21/1607 | Lonapegsomatropin Ascendis Pharma | Liechtenstein | 31.1.2022 |
| EU/1/21/1608 | Wegovy | Norway | 12.1.2022 |
| EU/1/21/1608 | Wegovy | Iceland | 19.1.2022 |
| EU/1/21/1608 | Wegovy | Liechtenstein | 31.1.2022 |
| EU/1/21/1611 | Vildagliptin/Metformin hydrochloride Accord | Norway | 06.4.2022 |
| EU/1/21/1611 | Vildagliptin/Metformin hydrochloride Accord | Iceland | 19.4.2022 |
| EU/1/21/1611 | Vildagliptin/Metformin hydrochloride Accord | Liechtenstein | 31.3.2022 |
| EU/1/21/1612 | Apexxnar | Norway | 22.2.2022 |
| EU/1/21/1612 | Apexxnar | Iceland | 22.2.2022 |
| EU/1/21/1612 | Apexxnar | Liechtenstein | 28.2.2022 |
| EU/1/21/1615 | Padcev | Norway | 21.4.2022 |
| EU/1/21/1615 | Padcev | Iceland | 4.5.2022 |
| EU/1/21/1615 | Padcev | Liechtenstein | 30.4.2022 |
| EU/1/21/1616 | Kerendia | Norway | 22.2.2022 |
| EU/1/21/1616 | Kerendia | Iceland | 24.2.2022 |
| EU/1/21/1616 | Kerendia | Liechtenstein | 28.2.2022 |
| EU/1/21/1617 | Ngenla | Norway | 22.2.2022 |
| EU/1/21/1617 | Ngenla | Iceland | 22.2.2022 |
| EU/1/21/1617 | Ngenla | Liechtenstein | 28.2.2022 |
| EU/1/21/1619 | Sitagliptin/Metformin hydrochloride Mylan | Norway | 24.3.2022 |
| EU/1/21/1619 | Sitagliptin/Metformin hydrochloride Mylan | Iceland | 15.3.2022 |
| EU/1/21/1619 | Sitagliptin/Metformin hydrochloride Mylan | Liechtenstein | 28.2.2022 |
| EU/1/21/1620 | Sapropterin Dipharma | Norway | 22.2.2022 |
| EU/1/21/1620 | Sapropterin Dipharma | Iceland | 22.2.2022 |
| EU/1/21/1620 | Sapropterin Dipharma | Liechtenstein | 28.2.2022 |
| EU/1/21/1621 | OKEDI | Norway | 21.2.2022 |
| EU/1/21/1621 | OKEDI | Iceland | 16.2.2022 |
| EU/1/21/1621 | OKEDI | Liechtenstein | 28.2.2022 |
| EU/1/21/1622 | Oxbryta | Norway | 21.2.2022 |
| EU/1/21/1622 | Oxbryta | Iceland | 22.2.2022 |
| EU/1/21/1622 | Oxbryta | Liechtenstein | 28.2.2022 |
| EU/1/21/1623 | Saphnelo | Norway | 21.2.2022 |
| EU/1/21/1623 | Saphnelo | Iceland | 21.2.2022 |
| EU/1/21/1623 | Saphnelo | Liechtenstein | 28.2.2022 |
| EU/1/21/1624 | Covid-19 Vaccine (inactivated, adjuvanted) Valneva | Norway | 27.6.2022 |
| EU/1/21/1624 | COVID-19 Vaccine (inactivated, adjuvanted) Valneva | Iceland | 28.6.2022 |
| EU/1/21/1624 | COVID-19 Vaccine (inactivated, adjuvanted) Valneva | Liechtenstein | 30.6.2022 |
| EU/1/22/1625 | Paxlovid | Norway | 28.1.2022 |
| EU/1/22/1625 | Paxlovid | Iceland | 1.2.2022 |
| EU/1/22/1625 | Paxlovid | Liechtenstein | 31.1.2022 |
| EU/1/22/1628 | Sondelbay | Norway | 7.4.2022 |
| EU/1/22/1628 | Sondelbay | Iceland | 20.4.2022 |
| EU/1/22/1628 | Sondelbay | Liechtenstein | 31.3.2022 |
| EU/1/22/1629 | Zolsketil pegylated liposomal | Iceland | 10.6.2022 |
| EU/1/22/1629 | Zolsketil pegylated liposomal | Liechtenstein | 31.5.2022 |
| EU/1/22/1630 | Kimmtrak | Norway | 12.4.2022 |
| EU/1/22/1630 | Kimmtrak | Iceland | 27.4.2022 |
| EU/1/22/1630 | Kimmtrak | Liechtenstein | 30.4.2022 |
| EU/1/22/1631 | Breyanzi | Norway | 20.4.2022 |
| EU/1/22/1631 | Breyanzi | Iceland | 4.5.2022 |
| EU/1/22/1631 | Breyanzi | Liechtenstein | 30.4.2022 |
| EU/1/22/1632 | Stimufend | Norway | 7.4.2022 |
| EU/1/22/1632 | Stimufend | Iceland | 20.4.2022 |
| EU/1/22/1632 | Stimufend | Liechtenstein | 31.3.2022 |
| EU/1/22/1633 | Sitagliptin Accord | Norway | 16.5.2022 |
| EU/1/22/1633 | Sitagliptin Accord | Iceland | 17.5.2022 |
| EU/1/22/1633 | Sitagliptin Accord | Liechtenstein | 30.4.2022 |
| EU/1/22/1634 | Dimethyl Fumarate Mylan | Norway | 23.5.2022 |
| EU/1/22/1634 | Dimethyl Fumarate Mylan | Iceland | 18.5.2022 |
| EU/1/22/1634 | Dimethyl fumarate Mylan | Liechtenstein | 31.5.2022 |
| EU/1/22/1635 | Dimethyl fumarate Polpharma | Norway | 20.5.2022 |
| EU/1/22/1635 | Dimethyl fumarate Polpharma | Iceland | 19.5.2022 |
| EU/1/22/1635 | Dimethyl fumarate Polpharma | Liechtenstein | 31.5.2022 |
| EU/1/22/1637 | Dimethyl fumarate Neuraxpharm | Norway | 20.5.2022 |
| EU/1/22/1637 | Dimethyl fumarate Neuraxpharm | Iceland | 19.5.2022 |
| EU/1/22/1637 | Dimethyl fumarate Neuraxpharm | Liechtenstein | 31.5.2022 |
| EU/1/22/1638 | Quviviq | Norway | 20.5.2022 |
| EU/1/22/1638 | Quviviq | Iceland | 28.6.2022 |
| EU/1/22/1638 | Quviviq | Liechtenstein | 30.4.2022 |
| EU/1/22/1639 | Truvelog Mix 30 | Norway | 29.4.2022 |
| EU/1/22/1639 | Truvelog Mix 30 | Iceland | 12.5.2022 |
| EU/1/22/1639 | Truvelog Mix 30 | Liechtenstein | 30.4.2022 |
| EU/1/22/1640 | Amversio | Norway | 20.5.2022 |
| EU/1/22/1640 | Amversio | Iceland | 19.5.2022 |
| EU/1/22/1640 | Amversio | Liechtenstein | 31.5.2022 |
| EU/1/22/1641 | PreHevbri | Norway | 16.5.2022 |
| EU/1/22/1641 | PreHevbri | Iceland | 18.5.2022 |
| EU/1/22/1641 | PreHevbri | Liechtenstein | 30.4.2022 |
| EU/1/22/1642 | Orgovyx | Norway | 16.5.2022 |
| EU/1/22/1642 | Orgovyx | Iceland | 12.5.2022 |
| EU/1/22/1642 | Orgovyx | Liechtenstein | 30.4.2022 |
| EU/1/22/1643 | Kapruvia | Norway | 25.4.2022 |
| EU/1/22/1643 | Kapruvia | Iceland | 11.5.2022 |
| EU/1/22/1643 | Kapruvia | Liechtenstein | 30.4.2022 |
| EU/1/22/1644 | Inpremzia | Norway | 20.5.2022 |
| EU/1/22/1644 | Inpremzia | Iceland | 18.5.2022 |
| EU/1/22/1644 | Inpremzia | Liechtenstein | 30.4.2022 |
| EU/1/22/1645 | Vydura | Norway | 29.4.2022 |
| EU/1/22/1645 | Vydura | Iceland | 11.5.2022 |
| EU/1/22/1645 | Vydura | Liechtenstein | 30.4.2022 |
| EU/1/22/1646 | Amifampridine SERB | Norway | 31.5.2022 |
| EU/1/22/1646 | Amifampridine SERB | Liechtenstein | 31.5.2022 |
| EU/1/22/1647 | Camcevi | Norway | 31.5.2022 |
| EU/1/22/1647 | Camcevi | Iceland | 9.6.2022 |
| EU/1/22/1647 | Camcevi | Liechtenstein | 31.5.2022 |
| EU/1/22/1648 | Carvykti | Norway | 31.5.2022 |
| EU/1/22/1648 | Carvykti | Iceland | 9.6.2022 |
| EU/1/22/1648 | Carvykti | Liechtenstein | 31.5.2022 |
| EU/1/22/1649 | Lunsumio | Norway | 16.6.2022 |
| EU/1/22/1649 | Lunsumio | Iceland | 15.6.2022 |
| EU/1/22/1649 | Lunsumio | Liechtenstein | 30.6.2022 |
| EU/1/22/1650 | Tabrecta | Liechtenstein | 30.6.2022 |
| EU/1/22/1651 | Evusheld | Norway | 28.3.2022 |
| EU/1/22/1651 | Evusheld | Iceland | 30.3.2022 |
| EU/1/22/1651 | Evusheld | Liechtenstein | 31.3.2022 |
| EU/1/22/1652 | Filsuvez | Liechtenstein | 30.6.2022 |
| EU/1/22/1655 | Pirfenidone AET | Liechtenstein | 30.6.2022 |
| EU/1/22/1659 | Xenpozyme | Liechtenstein | 30.6.2022 |
| EU/2/21/279 | Zenalpha | Norway | 7.1.2022 |
| EU/2/21/280 | Imoxat | Norway | 7.1.2022 |
| EU/2/21/281 | CircoMax | Norway | 17.1.2022 |
| EU/2/21/281 | CircoMax | Liechtenstein | 31.1.2022 |
| EU/2/22/282 | RenuTend | Norway | 29.4.2022 |
| EU/2/22/282 | RenuTend | Iceland | 24.5.2022 |
| EU/2/22/282 | RenuTend | Liechtenstein | 30.4.2022 |
| EU/2/22/283 | Chanaxin | Norway | 9.6.2022 |
| EU/2/22/283 | Chanaxin | Iceland | 14.6.2022 |
| EU/2/22/283 | Chanaxin | Liechtenstein | 30.4.2022 |

EU-Number

Product

Country

Date of authorisation

EU/1/21/1540

Dasatinib Accord

Norway

7.4.2022

EU/1/21/1540

Dasatinib Accord

Iceland

8.4.2022

EU/1/21/1540

Dasatinib Accord

Liechtenstein

31.3.2022

EU/1/21/1541

Dasatinib Accordpharma

Norway

7.4.2022

EU/1/21/1541

Dasatinib Accordpharma

Iceland

8.4.2022

EU/1/21/1541

Dasatinib Accordpharma

Liechtenstein

31.3.2022

EU/1/21/1569

QINLOCK

Norway

11.1.2022

EU/1/21/1578

Ontilyv

Norway

25.2.2022

EU/1/21/1578

Ontilyv

Iceland

24.2.2022

EU/1/21/1578

Ontilyv

Liechtenstein

28.2.2022

EU/1/21/1579

Nexviadyme

Liechtenstein

30.6.2022

EU/1/21/1586

Voraxaze

Norway

24.1.2022

EU/1/21/1586

Voraxaze

Iceland

10.2.2022

EU/1/21/1586

Voraxaze

Liechtenstein

31.1.2022

EU/1/21/1596

Tepmetko

Norway

22.2.2022

EU/1/21/1596

Tepmetko

Iceland

22.2.2022

EU/1/21/1596

Tepmetko

Liechtenstein

28.2.2022

EU/1/21/1598

Sitagliptin SUN

Norway

3.1.2022

EU/1/21/1599

Vyepti

Norway

7.2.2022

EU/1/21/1599

Vyepti

Iceland

28.1.2022

EU/1/21/1599

Vyepti

Liechtenstein

31.1.2022

EU/1/21/1600

Tecovirimat SIGA

Norway

17.1.2022

EU/1/21/1600

Tecovirimat SIGA

Iceland

14.1.2022

EU/1/21/1600

Tecovirimat SIGA

Liechtenstein

31.1.2022

EU/1/21/1602

Uplizna

Norway

16.5.2022

EU/1/21/1602

Uplizna

Iceland

13.5.2022

EU/1/21/1602

Uplizna

Liechtenstein

30.4.2022

EU/1/21/1603

Lumykras

Norway

11.1.2022

EU/1/21/1603

Lumykras

Iceland

25.1.2022

EU/1/21/1603

Lumykras

Liechtenstein

31.1.2022

EU/1/21/1604

Riltrava Aerosphere

Norway

11.1.2022

EU/1/21/1604

Riltrava Aerosphere

Iceland

19.1.2022

EU/1/21/1604

Riltrava Aerosphere

Liechtenstein

31.1.2022

EU/1/21/1605

Tavneos

Norway

19.1.2022

EU/1/21/1605

Tavneos

Iceland

14.2.2022

EU/1/21/1605

Tavneos

Liechtenstein

31.1.2022

EU/1/21/1606

Yselty

Norway

22.6.2022

EU/1/21/1606

Yselty

Iceland

21.6.2022

EU/1/21/1606

Yselty

Liechtenstein

30.6.2022

EU/1/21/1607

Lonapegsomatropin Ascendis Pharma

Norway

21.1.2022

EU/1/21/1607

Lonapegsomatropin Ascendis Pharma

Iceland

1.2.2022

EU/1/21/1607

Lonapegsomatropin Ascendis Pharma

Liechtenstein

31.1.2022

EU/1/21/1608

Wegovy

Norway

12.1.2022

EU/1/21/1608

Wegovy

Iceland

19.1.2022

EU/1/21/1608

Wegovy

Liechtenstein

31.1.2022

EU/1/21/1611

Vildagliptin/Metformin hydrochloride Accord

Norway

06.4.2022

EU/1/21/1611

Vildagliptin/Metformin hydrochloride Accord

Iceland

19.4.2022

EU/1/21/1611

Vildagliptin/Metformin hydrochloride Accord

Liechtenstein

31.3.2022

EU/1/21/1612

Apexxnar

Norway

22.2.2022

EU/1/21/1612

Apexxnar

Iceland

22.2.2022

EU/1/21/1612

Apexxnar

Liechtenstein

28.2.2022

EU/1/21/1615

Padcev

Norway

21.4.2022

EU/1/21/1615

Padcev

Iceland

4.5.2022

EU/1/21/1615

Padcev

Liechtenstein

30.4.2022

EU/1/21/1616

Kerendia

Norway

22.2.2022

EU/1/21/1616

Kerendia

Iceland

24.2.2022

EU/1/21/1616

Kerendia

Liechtenstein

28.2.2022

EU/1/21/1617

Ngenla

Norway

22.2.2022

EU/1/21/1617

Ngenla

Iceland

22.2.2022

EU/1/21/1617

Ngenla

Liechtenstein

28.2.2022

EU/1/21/1619

Sitagliptin/Metformin hydrochloride Mylan

Norway

24.3.2022

EU/1/21/1619

Sitagliptin/Metformin hydrochloride Mylan

Iceland

15.3.2022

EU/1/21/1619

Sitagliptin/Metformin hydrochloride Mylan

Liechtenstein

28.2.2022

EU/1/21/1620

Sapropterin Dipharma

Norway

22.2.2022

EU/1/21/1620

Sapropterin Dipharma

Iceland

22.2.2022

EU/1/21/1620

Sapropterin Dipharma

Liechtenstein

28.2.2022

EU/1/21/1621

OKEDI

Norway

21.2.2022

EU/1/21/1621

OKEDI

Iceland

16.2.2022

EU/1/21/1621

OKEDI

Liechtenstein

28.2.2022

EU/1/21/1622

Oxbryta

Norway

21.2.2022

EU/1/21/1622

Oxbryta

Iceland

22.2.2022

EU/1/21/1622

Oxbryta

Liechtenstein

28.2.2022

EU/1/21/1623

Saphnelo

Norway

21.2.2022

EU/1/21/1623

Saphnelo

Iceland

21.2.2022

EU/1/21/1623

Saphnelo

Liechtenstein

28.2.2022

EU/1/21/1624

Covid-19 Vaccine (inactivated, adjuvanted) Valneva

Norway

27.6.2022

EU/1/21/1624

COVID-19 Vaccine (inactivated, adjuvanted) Valneva

Iceland

28.6.2022

EU/1/21/1624

COVID-19 Vaccine (inactivated, adjuvanted) Valneva

Liechtenstein

30.6.2022

EU/1/22/1625

Paxlovid

Norway

28.1.2022

EU/1/22/1625

Paxlovid

Iceland

1.2.2022

EU/1/22/1625

Paxlovid

Liechtenstein

31.1.2022

EU/1/22/1628

Sondelbay

Norway

7.4.2022

EU/1/22/1628

Sondelbay

Iceland

20.4.2022

EU/1/22/1628

Sondelbay

Liechtenstein

31.3.2022

EU/1/22/1629

Zolsketil pegylated liposomal

Iceland

10.6.2022

EU/1/22/1629

Zolsketil pegylated liposomal

Liechtenstein

31.5.2022

EU/1/22/1630

Kimmtrak

Norway

12.4.2022

EU/1/22/1630

Kimmtrak

Iceland

27.4.2022

EU/1/22/1630

Kimmtrak

Liechtenstein

30.4.2022

EU/1/22/1631

Breyanzi

Norway

20.4.2022

EU/1/22/1631

Breyanzi

Iceland

4.5.2022

EU/1/22/1631

Breyanzi

Liechtenstein

30.4.2022

EU/1/22/1632

Stimufend

Norway

7.4.2022

EU/1/22/1632

Stimufend

Iceland

20.4.2022

EU/1/22/1632

Stimufend

Liechtenstein

31.3.2022

EU/1/22/1633

Sitagliptin Accord

Norway

16.5.2022

EU/1/22/1633

Sitagliptin Accord

Iceland

17.5.2022

EU/1/22/1633

Sitagliptin Accord

Liechtenstein

30.4.2022

EU/1/22/1634

Dimethyl Fumarate Mylan

Norway

23.5.2022

EU/1/22/1634

Dimethyl Fumarate Mylan

Iceland

18.5.2022

EU/1/22/1634

Dimethyl fumarate Mylan

Liechtenstein

31.5.2022

EU/1/22/1635

Dimethyl fumarate Polpharma

Norway

20.5.2022

EU/1/22/1635

Dimethyl fumarate Polpharma

Iceland

19.5.2022

EU/1/22/1635

Dimethyl fumarate Polpharma

Liechtenstein

31.5.2022

EU/1/22/1637

Dimethyl fumarate Neuraxpharm

Norway

20.5.2022

EU/1/22/1637

Dimethyl fumarate Neuraxpharm

Iceland

19.5.2022

EU/1/22/1637

Dimethyl fumarate Neuraxpharm

Liechtenstein

31.5.2022

EU/1/22/1638

Quviviq

Norway

20.5.2022

EU/1/22/1638

Quviviq

Iceland

28.6.2022

EU/1/22/1638

Quviviq

Liechtenstein

30.4.2022

EU/1/22/1639

Truvelog Mix 30

Norway

29.4.2022

EU/1/22/1639

Truvelog Mix 30

Iceland

12.5.2022

EU/1/22/1639

Truvelog Mix 30

Liechtenstein

30.4.2022

EU/1/22/1640

Amversio

Norway

20.5.2022

EU/1/22/1640

Amversio

Iceland

19.5.2022

EU/1/22/1640

Amversio

Liechtenstein

31.5.2022

EU/1/22/1641

PreHevbri

Norway

16.5.2022

EU/1/22/1641

PreHevbri

Iceland

18.5.2022

EU/1/22/1641

PreHevbri

Liechtenstein

30.4.2022

EU/1/22/1642

Orgovyx

Norway

16.5.2022

EU/1/22/1642

Orgovyx

Iceland

12.5.2022

EU/1/22/1642

Orgovyx

Liechtenstein

30.4.2022

EU/1/22/1643

Kapruvia

Norway

25.4.2022

EU/1/22/1643

Kapruvia

Iceland

11.5.2022

EU/1/22/1643

Kapruvia

Liechtenstein

30.4.2022

EU/1/22/1644

Inpremzia

Norway

20.5.2022

EU/1/22/1644

Inpremzia

Iceland

18.5.2022

EU/1/22/1644

Inpremzia

Liechtenstein

30.4.2022

EU/1/22/1645

Vydura

Norway

29.4.2022

EU/1/22/1645

Vydura

Iceland

11.5.2022

EU/1/22/1645

Vydura

Liechtenstein

30.4.2022

EU/1/22/1646

Amifampridine SERB

Norway

31.5.2022

EU/1/22/1646

Amifampridine SERB

Liechtenstein

31.5.2022

EU/1/22/1647

Camcevi

Norway

31.5.2022

EU/1/22/1647

Camcevi

Iceland

9.6.2022

EU/1/22/1647

Camcevi

Liechtenstein

31.5.2022

EU/1/22/1648

Carvykti

Norway

31.5.2022

EU/1/22/1648

Carvykti

Iceland

9.6.2022

EU/1/22/1648

Carvykti

Liechtenstein

31.5.2022

EU/1/22/1649

Lunsumio

Norway

16.6.2022

EU/1/22/1649

Lunsumio

Iceland

15.6.2022

EU/1/22/1649

Lunsumio

Liechtenstein

30.6.2022

EU/1/22/1650

Tabrecta

Liechtenstein

30.6.2022

EU/1/22/1651

Evusheld

Norway

28.3.2022

EU/1/22/1651

Evusheld

Iceland

30.3.2022

EU/1/22/1651

Evusheld

Liechtenstein

31.3.2022

EU/1/22/1652

Filsuvez

Liechtenstein

30.6.2022

EU/1/22/1655

Pirfenidone AET

Liechtenstein

30.6.2022

EU/1/22/1659

Xenpozyme

Liechtenstein

30.6.2022

EU/2/21/279

Zenalpha

Norway

7.1.2022

EU/2/21/280

Imoxat

Norway

7.1.2022

EU/2/21/281

CircoMax

Norway

17.1.2022

EU/2/21/281

CircoMax

Liechtenstein

31.1.2022

EU/2/22/282

RenuTend

Norway

29.4.2022

EU/2/22/282

RenuTend

Iceland

24.5.2022

EU/2/22/282

RenuTend

Liechtenstein

30.4.2022

EU/2/22/283

Chanaxin

Norway

9.6.2022

EU/2/22/283

Chanaxin

Iceland

14.6.2022

EU/2/22/283

Chanaxin

Liechtenstein

30.4.2022

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2022:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/11/699 | Fampyra | Norway | 9.5.2022 |
| EU/1/11/699 | Fampyra | Liechtenstein | 30.4.2022 |
| EU/1/11/749 | Caprelsa | Norway | 24.1.2022 |
| EU/1/11/749 | Caprelsa | Iceland | 20.1.2022 |
| EU/1/11/749 | Caprelsa | Liechtenstein | 31.1.2022 |
| EU/1/12/782 | Kalydeco | Norway | 20.5.2022 |
| EU/1/12/782 | Kalydeco | Liechtenstein | 30.4.2022 |
| EU/1/12/784 | Cuprymina | Iceland | 28.6.2022 |
| EU/1/12/784 | Cuprymina | Liechtenstein | 30.6.2022 |
| EU/1/13/818 | Bosulif | Norway | 16.5.2022 |
| EU/1/13/818 | Bosulif | Iceland | 20.4.2022 |
| EU/1/13/818 | Bosulif | Liechtenstein | 31.3.2022 |
| EU/1/13/875 | Deltyba | Norway | 30.3.2022 |
| EU/1/13/875 | Deltyba | Iceland | 6.4.2022 |
| EU/1/13/875 | Deltyba | Liechtenstein | 31.3.2022 |
| EU/1/13/901 | Sirturo | Norway | 26.1.2022 |
| EU/1/13/901 | Sirturo | Iceland | 14.1.2022 |
| EU/1/13/901 | Sirturo | Liechtenstein | 31.1.2022 |
| EU/1/13/902 | Translarna | Iceland | 28.6.2022 |
| EU/1/13/902 | Translarna | Liechtenstein | 30.6.2022 |
| EU/1/14/987 | Holoclar | Norway | 8.4.2022 |
| EU/1/14/987 | Holoclar | Iceland | 11.1.2022 |
| EU/1/14/987 | Holoclar | Liechtenstein | 31.1.2022 |
| EU/1/15/1078 | Natpar | Norway | 19.4.2022 |
| EU/1/15/1078 | Natpar | Iceland | 6.4.2022 |
| EU/1/15/1078 | Natpar | Liechtenstein | 31.3.2022 |
| EU/1/15/999 | Zykadia | Norway | 22.2.2022 |
| EU/1/15/999 | Zykadia | Iceland | 22.2.2022 |
| EU/1/15/999 | Zykadia | Liechtenstein | 28.2.2022 |
| EU/1/16/1086 | Tagrisso | Norway | 6.4.2022 |
| EU/1/16/1086 | Tagrisso | Iceland | 20.4.2022 |
| EU/1/16/1086 | Tagrisso | Liechtenstein | 31.3.2022 |
| EU/1/16/1089 | Pandemic influenza vaccine H5N1 AstraZeneca | Norway | 8.4.2022 |
| EU/1/16/1089 | Pandemic influenza vaccine H5N1 AstraZeneca | Iceland | 16.3.2022 |
| EU/1/16/1089 | Pandemic influenza vaccine H5N1 AstraZeneca | Liechtenstein | 31.3.2022 |
| EU/1/16/1101 | Darzalex | Norway | 21.1.2022 |
| EU/1/16/1101 | Darzalex | Iceland | 14.1.2022 |
| EU/1/16/1101 | Darzalex | Liechtenstein | 31.1.2022 |
| EU/1/16/1139 | Ocaliva | Norway | 24.1.2022 |
| EU/1/16/1139 | Ocaliva | Iceland | 21.1.2022 |
| EU/1/16/1139 | Ocaliva | Liechtenstein | 31.1.2022 |
| EU/1/16/1152 | Roteas | Norway | 13.1.2022 |
| EU/1/16/1152 | Roteas | Iceland | 11.1.2022 |
| EU/1/16/1152 | Roteas | Liechtenstein | 31.1.2022 |
| EU/1/16/1154 | Vemlidy | Norway | 4.1.2022 |
| EU/1/16/1154 | Vemlidy | Iceland | 5.1.2022 |
| EU/1/16/1154 | Vemlidy | Liechtenstein | 31.1.2022 |
| EU/1/16/1155 | Kyntheum | Norway | 29.4.2022 |
| EU/1/16/1155 | Kyntheum | Iceland | 11.5.2022 |
| EU/1/16/1155 | Kyntheum | Liechtenstein | 30.4.2022 |
| EU/1/16/1171 | Ledaga | Norway | 17.1.2022 |
| EU/1/16/1171 | Ledaga | Iceland | 14.1.2022 |
| EU/1/16/1171 | Ledaga | Liechtenstein | 31.1.2022 |
| EU/1/17/1172 | Jylamvo | Norway | 24.1.2022 |
| EU/1/17/1172 | Jylamvo | Iceland | 5.1.2022 |
| EU/1/17/1172 | Jylamvo | Liechtenstein | 31.1.2022 |
| EU/1/17/1174 | Rolufta Ellipta | Norway | 14.1.2022 |
| EU/1/17/1174 | Rolufta Ellipta | Iceland | 14.1.2022 |
| EU/1/17/1174 | Rolufta Ellipta | Liechtenstein | 31.1.2022 |
| EU/1/17/1175 | Daptomycin Hospira | Norway | 13.1.2022 |
| EU/1/17/1175 | Daptomycin Hospira | Iceland | 25.1.2022 |
| EU/1/17/1176 | Yargesa | Norway | 24.1.2022 |
| EU/1/17/1176 | Yargesa | Iceland | 20.1.2022 |
| EU/1/17/1176 | Yargesa | Liechtenstein | 31.1.2022 |
| EU/1/17/1178 | Xeljanz | Norway | 14.3.2022 |
| EU/1/17/1178 | Xeljanz | Iceland | 15.3.2022 |
| EU/1/17/1178 | Xeljanz | Liechtenstein | 31.3.2022 |
| EU/1/17/1179 | Veltassa | Norway | 6.4.2022 |
| EU/1/17/1179 | Veltassa | Iceland | 19.4.2022 |
| EU/1/17/1179 | Veltassa | Liechtenstein | 31.3.2022 |
| EU/1/17/1181 | Spherox | Norway | 8.6.2022 |
| EU/1/17/1181 | Spherox | Iceland | 19.5.2022 |
| EU/1/17/1181 | Spherox | Liechtenstein | 30.4.2022 |
| EU/1/17/1182 | Emtricitabine/Tenofovir disoproxil Krka d.d | Norway | 24.1.2022 |
| EU/1/17/1182 | Emtricitabine/Tenofovir disoproxil Krka d.d. | Iceland | 21.1.2022 |
| EU/1/17/1182 | Emtricitabine /Tenofovir disoproxil Krka d.d. | Liechtenstein | 31.1.2022 |
| EU/1/17/1184 | Riximyo | Norway | 22.2.2022 |
| EU/1/17/1184 | Riximyo | Iceland | 23.2.2022 |
| EU/1/17/1184 | Riximyo | Liechtenstein | 28.2.2022 |
| EU/1/17/1185 | Rixathon | Norway | 14.3.2022 |
| EU/1/17/1185 | Rixathon | Iceland | 15.3.2022 |
| EU/1/17/1185 | Rixathon | Liechtenstein | 28.2.2022 |
| EU/1/17/1186 | Axumin | Norway | 16.2.2022 |
| EU/1/17/1186 | Axumin | Iceland | 16.2.2022 |
| EU/1/17/1186 | Axumin | Liechtenstein | 28.2.2022 |
| EU/1/17/1187 | Trumenba | Norway | 9.5.2022 |
| EU/1/17/1187 | Trumenba | Iceland | 11.5.2022 |
| EU/1/17/1187 | Trumenba | Liechtenstein | 30.4.2022 |
| EU/1/17/1188 | Spinraza | Norway | 7.2.2022 |
| EU/1/17/1188 | Spinraza | Iceland | 11.2.2022 |
| EU/1/17/1188 | Spinraza | Liechtenstein | 31.1.2022 |
| EU/1/17/1189 | Elmiron | Norway | 26.1.2022 |
| EU/1/17/1189 | Elmiron | Iceland | 21.1.2022 |
| EU/1/17/1189 | Elmiron | Liechtenstein | 31.1.2022 |
| EU/1/17/1190 | Ivabradine Accord | Norway | 18.2.2022 |
| EU/1/17/1190 | Ivabradine Accord | Iceland | 22.2.2022 |
| EU/1/17/1190 | Ivabradine Accord | Liechtenstein | 28.2.2022 |
| EU/1/17/1191 | Qarziba | Norway | 27.1.2022 |
| EU/1/17/1191 | Qarziba | Iceland | 19.1.2022 |
| EU/1/17/1191 | Qarziba | Liechtenstein | 31.1.2022 |
| EU/1/17/1192 | Brineura | Liechtenstein | 31.3.2022 |
| EU/1/17/1192 | Brineura | Norway | 15.5.2022 |
| EU/1/17/1193 | Refixia | Norway | 5.4.2022 |
| EU/1/17/1193 | Refixia | Iceland | 15.3.2022 |
| EU/1/17/1193 | Refixia | Liechtenstein | 28.2.2022 |
| EU/1/17/1194 | Febuxostat Mylan | Norway | 21.2.2022 |
| EU/1/17/1194 | Febuxostat Mylan | Iceland | 23.2.2022 |
| EU/1/17/1194 | Febuxostat Mylan | Liechtenstein | 28.2.2022 |
| EU/1/17/1195 | Erelzi | Iceland | 27.4.2022 |
| EU/1/17/1195 | Erelzi | Liechtenstein | 30.4.2022 |
| EU/1/17/1196 | Kevzara | Norway | 9.5.2022 |
| EU/1/17/1196 | Kevzara | Iceland | 11.5.2022 |
| EU/1/17/1196 | Kevzara | Liechtenstein | 30.4.2022 |
| EU/1/17/1197 | Oxervate | Norway | 12.4.2022 |
| EU/1/17/1197 | Oxervate | Iceland | 20.4.2022 |
| EU/1/17/1197 | Oxervate | Liechtenstein | 31.3.2022 |
| EU/1/17/1200 | Besponsa | Norway | 22.2.2022 |
| EU/1/17/1200 | Besponsa | Iceland | 21.2.2022 |
| EU/1/17/1200 | Besponsa | Liechtenstein | 28.2.2022 |
| EU/1/17/1201 | Skilarence | Norway | 24.2.2022 |
| EU/1/17/1201 | Skilarence | Iceland | 24.2.2022 |
| EU/1/17/1201 | Skilarence | Liechtenstein | 28.2.2022 |
| EU/1/17/1202 | Ucedane | Norway | 29.4.2022 |
| EU/1/17/1202 | Ucedane | Iceland | 25.4.2022 |
| EU/1/17/1202 | Ucedane | Liechtenstein | 31.3.2022 |
| EU/1/17/1203 | Insulin lispro Sanofi | Norway | 29.4.2022 |
| EU/1/17/1203 | Insulin lispro Sanofi | Iceland | 3.5.2022 |
| EU/1/17/1203 | Insulin lispro Sanofi | Liechtenstein | 31.3.2022 |
| EU/1/17/1205 | Blitzima | Norway | 29.4.2022 |
| EU/1/17/1205 | Blitzima | Iceland | 6.5.2022 |
| EU/1/17/1205 | Blitzima | Liechtenstein | 30.4.2022 |
| EU/1/17/1208 | Trimbow | Norway | 31.3.2022 |
| EU/1/17/1208 | Trimbow | Iceland | 19.4.2022 |
| EU/1/17/1208 | Trimbow | Liechtenstein | 31.3.2022 |
| EU/1/17/1209 | Reagila | Norway | 20.4.2022 |
| EU/1/17/1209 | Reagila | Iceland | 20.4.2022 |
| EU/1/17/1209 | Reagila | Liechtenstein | 30.4.2022 |
| EU/1/17/1210 | Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva | Norway | 31.5.2022 |
| EU/1/7/1210 | Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva | Iceland | 9.6.2022 |
| EU/1/17/1210 | Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva | Liechtenstein | 31.5.2022 |
| EU/1/17/1212 | Mavenclad | Norway | 29.4.2022 |
| EU/1/17/1212 | Mavenclad | Iceland | 11.5.2022 |
| EU/1/17/1212 | Mavenclad | Liechtenstein | 30.4.2022 |
| EU/1/17/1213 | Maviret | Iceland | 20.4.2022 |
| EU/1/17/1213 | Maviret | Liechtenstein | 31.3.2022 |
| EU/1/17/1216 | Imraldi | Norway | 9.5.2022 |
| EU/1/17/1216 | Imraldi | Iceland | 17.5.2022 |
| EU/1/17/1216 | Imraldi | Liechtenstein | 30.4.2022 |
| EU/1/17/1218 | Rydapt | Iceland | 10.6.2022 |
| EU/1/17/1218 | Rydapt | Liechtenstein | 31.5.2022 |
| EU/1/17/1220 | Tecentriq | Norway | 29.4.2022 |
| EU/1/17/1220 | Tecentriq | Iceland | 6.5.2022 |
| EU/1/17/1220 | Tecentriq | Liechtenstein | 30.4.2022 |
| EU/1/17/1221 | Kisqali | Norway | 20.4.2022 |
| EU/1/17/1221 | Kisqali | Iceland | 27.4.2022 |
| EU/1/17/1221 | Kisqali | Liechtenstein | 30.4.2022 |
| EU/1/17/1222 | Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan | Iceland | 9.6.2022 |
| EU/1/17/1222 | Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan | Liechtenstein | 31.5.2022 |
| EU/1/17/1223 | Vosevi | Norway | 20.5.2022 |
| EU/1/17/1223 | Vosevi | Liechtenstein | 31.5.2022 |
| EU/1/17/1224 | Xermelo | Liechtenstein | 30.6.2022 |
| EU/1/17/1225 | Symtuza | Norway | 31.5.2022 |
| EU/1/17/1225 | Symtuza | Iceland | 9.6.2022 |
| EU/1/17/1225 | Symtuza | Liechtenstein | 31.5.2022 |
| EU/1/17/1227 | Entecavir Mylan | Liechtenstein | 30.6.2022 |
| EU/1/17/1250 | Rubraca | Norway | 24.3.2022 |
| EU/1/17/1250 | Rubraca | Iceland | 16.3.2022 |
| EU/1/17/1250 | Rubraca | Liechtenstein | 31.3.2022 |
| EU/1/17/1262 | Crysvita | Norway | 11.2.2022 |
| EU/1/17/1262 | Crysvita | Iceland | 25.1.2022 |
| EU/1/17/1262 | Crysvita | Liechtenstein | 31.1.2022 |
| EU/1/18/1345 | Ondexxya | Norway | 30.6.2022 |
| EU/1/18/1345 | Ondexxya | Iceland | 17.5.2022 |
| EU/1/18/1345 | Ondexxya | Liechtenstein | 30.4.2022 |
| EU/1/19/1355 | Lorviqua | Iceland | 25.4.2022 |
| EU/1/19/1355 | Lorviqua | Liechtenstein | 30.4.2022 |
| EU/1/19/1360 | Waylivra | Norway | 24.2.2022 |
| EU/1/19/1360 | Waylivra | Iceland | 21.2.2022 |
| EU/1/19/1360 | Waylivra | Liechtenstein | 28.2.2022 |
| EU/1/20/1437 | Dovprela | Liechtenstein | 30.6.2022 |
| EU/1/20/1443 | Zolgensma | Norway | 31.5.2022 |
| EU/1/20/1443 | Zolgensma | Iceland | 9.6.2022 |
| EU/1/20/1443 | Zolgensma | Liechtenstein | 31.5.2022 |
| EU/1/20/1446 | Hepcludex | Liechtenstein | 30.6.2022 |
| EU/1/20/1459 | Veklury | Norway | 29.4.2022 |
| EU/1/20/1459 | Veklury | Iceland | 4.5.2022 |
| EU/1/20/1459 | Veklury | Liechtenstein | 30.4.2022 |
| EU/1/20/1460 | Rozlytrek | Liechtenstein | 31.5.2022 |
| EU/1/20/1474 | BLENREP | Liechtenstein | 30.6.2022 |
| EU/1/20/1525 | COVID- 19 Vaccine Janssen (JCOVDEN) | Norway | 24.1.2022 |
| EU/1/20/1525 | COVID-19 Vaccine Janssen (JCOVDEN) | Iceland | 14.2.2022 |
| EU/1/20/1525 | COVID-19 Vaccine Janssen (JCOVDEN) | Liechtenstein | 31.1.2022 |
| EU/1/20/1527 | Retsevmo | Norway | 26.1.2022 |
| EU/1/20/1527 | Retsevmo | Iceland | 4.1.2022 |
| EU/1/21/1535 | Pemazyre | Norway | 22.2.2022 |
| EU/1/21/1535 | Pemazyre | Iceland | 23.2.2022 |
| EU/1/21/1535 | Pemazyre | Liechtenstein | 28.2.2022 |
| EU/1/21/1537 | NEXPOVIO | Norway | 2.6.2022 |
| EU/1/21/1537 | NEXPOVIO | Iceland | 19.5.2022 |
| EU/1/21/1537 | NEXPOVIO | Liechtenstein | 31.5.2022 |
| EU/1/21/1538 | Jemperli | Norway | 22.2.2022 |
| EU/1/21/1538 | Jemperli | Iceland | 22.2.2022 |
| EU/1/21/1538 | Jemperli | Liechtenstein | 28.2.2022 |
| EU/1/21/1539 | Abecma | Liechtenstein | 30.6.2022 |
| EU/1/21/1552 | Koselugo | Norway | 12.5.2022 |
| EU/1/21/1552 | Koselugo | Liechtenstein | 30.4.2022 |
| EU/2/16/203 | VarroMed | Norway | 24.1.2022 |
| EU/2/16/203 | VarroMed | Iceland | 21.1.2022 |
| EU/2/16/203 | VarroMed | Liechtenstein | 31.1.2022 |
| EU/2/17/205 | Cytopoint | Norway | 29.6.2022 |
| EU/2/17/205 | Cytopoint | Liechtenstein | 30.4.2022 |
| EU/2/17/206 | Credelio | Norway | 29.6.2022 |
| EU/2/17/206 | Credelio | Liechtenstein | 30.4.2022 |
| EU/2/17/207 | Zulvac BTV | Norway | 29.6.2022 |
| EU/2/17/207 | Zulvac BTV | Liechtenstein | 30.4.2022 |
| EU/2/17/209 | RESPIPORC FLUpan H1N1 | Norway | 29.6.2022 |
| EU/2/17/209 | RESPIPORC FLUpan H1N1 | Liechtenstein | 30.4.2022 |
| EU/2/17/210 | Zeleris | Norway | 30.6.2022 |
| EU/2/17/210 | Zeleris | Iceland | 18.5.2022 |
| EU/2/17/210 | Zeleris | Liechtenstein | 31.5.2022 |

EU-Number

Product

Country

Date of authorisation

EU/1/11/699

Fampyra

Norway

9.5.2022

EU/1/11/699

Fampyra

Liechtenstein

30.4.2022

EU/1/11/749

Caprelsa

Norway

24.1.2022

EU/1/11/749

Caprelsa

Iceland

20.1.2022

EU/1/11/749

Caprelsa

Liechtenstein

31.1.2022

EU/1/12/782

Kalydeco

Norway

20.5.2022

EU/1/12/782

Kalydeco

Liechtenstein

30.4.2022

EU/1/12/784

Cuprymina

Iceland

28.6.2022

EU/1/12/784

Cuprymina

Liechtenstein

30.6.2022

EU/1/13/818

Bosulif

Norway

16.5.2022

EU/1/13/818

Bosulif

Iceland

20.4.2022

EU/1/13/818

Bosulif

Liechtenstein

31.3.2022

EU/1/13/875

Deltyba

Norway

30.3.2022

EU/1/13/875

Deltyba

Iceland

6.4.2022

EU/1/13/875

Deltyba

Liechtenstein

31.3.2022

EU/1/13/901

Sirturo

Norway

26.1.2022

EU/1/13/901

Sirturo

Iceland

14.1.2022

EU/1/13/901

Sirturo

Liechtenstein

31.1.2022

EU/1/13/902

Translarna

Iceland

28.6.2022

EU/1/13/902

Translarna

Liechtenstein

30.6.2022

EU/1/14/987

Holoclar

Norway

8.4.2022

EU/1/14/987

Holoclar

Iceland

11.1.2022

EU/1/14/987

Holoclar

Liechtenstein

31.1.2022

EU/1/15/1078

Natpar

Norway

19.4.2022

EU/1/15/1078

Natpar

Iceland

6.4.2022

EU/1/15/1078

Natpar

Liechtenstein

31.3.2022

EU/1/15/999

Zykadia

Norway

22.2.2022

EU/1/15/999

Zykadia

Iceland

22.2.2022

EU/1/15/999

Zykadia

Liechtenstein

28.2.2022

EU/1/16/1086

Tagrisso

Norway

6.4.2022

EU/1/16/1086

Tagrisso

Iceland

20.4.2022

EU/1/16/1086

Tagrisso

Liechtenstein

31.3.2022

EU/1/16/1089

Pandemic influenza vaccine H5N1 AstraZeneca

Norway

8.4.2022

EU/1/16/1089

Pandemic influenza vaccine H5N1 AstraZeneca

Iceland

16.3.2022

EU/1/16/1089

Pandemic influenza vaccine H5N1 AstraZeneca

Liechtenstein

31.3.2022

EU/1/16/1101

Darzalex

Norway

21.1.2022

EU/1/16/1101

Darzalex

Iceland

14.1.2022

EU/1/16/1101

Darzalex

Liechtenstein

31.1.2022

EU/1/16/1139

Ocaliva

Norway

24.1.2022

EU/1/16/1139

Ocaliva

Iceland

21.1.2022

EU/1/16/1139

Ocaliva

Liechtenstein

31.1.2022

EU/1/16/1152

Roteas

Norway

13.1.2022

EU/1/16/1152

Roteas

Iceland

11.1.2022

EU/1/16/1152

Roteas

Liechtenstein

31.1.2022

EU/1/16/1154

Vemlidy

Norway

4.1.2022

EU/1/16/1154

Vemlidy

Iceland

5.1.2022

EU/1/16/1154

Vemlidy

Liechtenstein

31.1.2022

EU/1/16/1155

Kyntheum

Norway

29.4.2022

EU/1/16/1155

Kyntheum

Iceland

11.5.2022

EU/1/16/1155

Kyntheum

Liechtenstein

30.4.2022

EU/1/16/1171

Ledaga

Norway

17.1.2022

EU/1/16/1171

Ledaga

Iceland

14.1.2022

EU/1/16/1171

Ledaga

Liechtenstein

31.1.2022

EU/1/17/1172

Jylamvo

Norway

24.1.2022

EU/1/17/1172

Jylamvo

Iceland

5.1.2022

EU/1/17/1172

Jylamvo

Liechtenstein

31.1.2022

EU/1/17/1174

Rolufta Ellipta

Norway

14.1.2022

EU/1/17/1174

Rolufta Ellipta

Iceland

14.1.2022

EU/1/17/1174

Rolufta Ellipta

Liechtenstein

31.1.2022

EU/1/17/1175

Daptomycin Hospira

Norway

13.1.2022

EU/1/17/1175

Daptomycin Hospira

Iceland

25.1.2022

EU/1/17/1176

Yargesa

Norway

24.1.2022

EU/1/17/1176

Yargesa

Iceland

20.1.2022

EU/1/17/1176

Yargesa

Liechtenstein

31.1.2022

EU/1/17/1178

Xeljanz

Norway

14.3.2022

EU/1/17/1178

Xeljanz

Iceland

15.3.2022

EU/1/17/1178

Xeljanz

Liechtenstein

31.3.2022

EU/1/17/1179

Veltassa

Norway

6.4.2022

EU/1/17/1179

Veltassa

Iceland

19.4.2022

EU/1/17/1179

Veltassa

Liechtenstein

31.3.2022

EU/1/17/1181

Spherox

Norway

8.6.2022

EU/1/17/1181

Spherox

Iceland

19.5.2022

EU/1/17/1181

Spherox

Liechtenstein

30.4.2022

EU/1/17/1182

Emtricitabine/Tenofovir disoproxil Krka d.d

Norway

24.1.2022

EU/1/17/1182

Emtricitabine/Tenofovir disoproxil Krka d.d.

Iceland

21.1.2022

EU/1/17/1182

Emtricitabine /Tenofovir disoproxil Krka d.d.

Liechtenstein

31.1.2022

EU/1/17/1184

Riximyo

Norway

22.2.2022

EU/1/17/1184

Riximyo

Iceland

23.2.2022

EU/1/17/1184

Riximyo

Liechtenstein

28.2.2022

EU/1/17/1185

Rixathon

Norway

14.3.2022

EU/1/17/1185

Rixathon

Iceland

15.3.2022

EU/1/17/1185

Rixathon

Liechtenstein

28.2.2022

EU/1/17/1186

Axumin

Norway

16.2.2022

EU/1/17/1186

Axumin

Iceland

16.2.2022

EU/1/17/1186

Axumin

Liechtenstein

28.2.2022

EU/1/17/1187

Trumenba

Norway

9.5.2022

EU/1/17/1187

Trumenba

Iceland

11.5.2022

EU/1/17/1187

Trumenba

Liechtenstein

30.4.2022

EU/1/17/1188

Spinraza

Norway

7.2.2022

EU/1/17/1188

Spinraza

Iceland

11.2.2022

EU/1/17/1188

Spinraza

Liechtenstein

31.1.2022

EU/1/17/1189

Elmiron

Norway

26.1.2022

EU/1/17/1189

Elmiron

Iceland

21.1.2022

EU/1/17/1189

Elmiron

Liechtenstein

31.1.2022

EU/1/17/1190

Ivabradine Accord

Norway

18.2.2022

EU/1/17/1190

Ivabradine Accord

Iceland

22.2.2022

EU/1/17/1190

Ivabradine Accord

Liechtenstein

28.2.2022

EU/1/17/1191

Qarziba

Norway

27.1.2022

EU/1/17/1191

Qarziba

Iceland

19.1.2022

EU/1/17/1191

Qarziba

Liechtenstein

31.1.2022

EU/1/17/1192

Brineura

Liechtenstein

31.3.2022

EU/1/17/1192

Brineura

Norway

15.5.2022

EU/1/17/1193

Refixia

Norway

5.4.2022

EU/1/17/1193

Refixia

Iceland

15.3.2022

EU/1/17/1193

Refixia

Liechtenstein

28.2.2022

EU/1/17/1194

Febuxostat Mylan

Norway

21.2.2022

EU/1/17/1194

Febuxostat Mylan

Iceland

23.2.2022

EU/1/17/1194

Febuxostat Mylan

Liechtenstein

28.2.2022

EU/1/17/1195

Erelzi

Iceland

27.4.2022

EU/1/17/1195

Erelzi

Liechtenstein

30.4.2022

EU/1/17/1196

Kevzara

Norway

9.5.2022

EU/1/17/1196

Kevzara

Iceland

11.5.2022

EU/1/17/1196

Kevzara

Liechtenstein

30.4.2022

EU/1/17/1197

Oxervate

Norway

12.4.2022

EU/1/17/1197

Oxervate

Iceland

20.4.2022

EU/1/17/1197

Oxervate

Liechtenstein

31.3.2022

EU/1/17/1200

Besponsa

Norway

22.2.2022

EU/1/17/1200

Besponsa

Iceland

21.2.2022

EU/1/17/1200

Besponsa

Liechtenstein

28.2.2022

EU/1/17/1201

Skilarence

Norway

24.2.2022

EU/1/17/1201

Skilarence

Iceland

24.2.2022

EU/1/17/1201

Skilarence

Liechtenstein

28.2.2022

EU/1/17/1202

Ucedane

Norway

29.4.2022

EU/1/17/1202

Ucedane

Iceland

25.4.2022

EU/1/17/1202

Ucedane

Liechtenstein

31.3.2022

EU/1/17/1203

Insulin lispro Sanofi

Norway

29.4.2022

EU/1/17/1203

Insulin lispro Sanofi

Iceland

3.5.2022

EU/1/17/1203

Insulin lispro Sanofi

Liechtenstein

31.3.2022

EU/1/17/1205

Blitzima

Norway

29.4.2022

EU/1/17/1205

Blitzima

Iceland

6.5.2022

EU/1/17/1205

Blitzima

Liechtenstein

30.4.2022

EU/1/17/1208

Trimbow

Norway

31.3.2022

EU/1/17/1208

Trimbow

Iceland

19.4.2022

EU/1/17/1208

Trimbow

Liechtenstein

31.3.2022

EU/1/17/1209

Reagila

Norway

20.4.2022

EU/1/17/1209

Reagila

Iceland

20.4.2022

EU/1/17/1209

Reagila

Liechtenstein

30.4.2022

EU/1/17/1210

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Norway

31.5.2022

EU/1/7/1210

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Iceland

9.6.2022

EU/1/17/1210

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Liechtenstein

31.5.2022

EU/1/17/1212

Mavenclad

Norway

29.4.2022

EU/1/17/1212

Mavenclad

Iceland

11.5.2022

EU/1/17/1212

Mavenclad

Liechtenstein

30.4.2022

EU/1/17/1213

Maviret

Iceland

20.4.2022

EU/1/17/1213

Maviret

Liechtenstein

31.3.2022

EU/1/17/1216

Imraldi

Norway

9.5.2022

EU/1/17/1216

Imraldi

Iceland

17.5.2022

EU/1/17/1216

Imraldi

Liechtenstein

30.4.2022

EU/1/17/1218

Rydapt

Iceland

10.6.2022

EU/1/17/1218

Rydapt

Liechtenstein

31.5.2022

EU/1/17/1220

Tecentriq

Norway

29.4.2022

EU/1/17/1220

Tecentriq

Iceland

6.5.2022

EU/1/17/1220

Tecentriq

Liechtenstein

30.4.2022

EU/1/17/1221

Kisqali

Norway

20.4.2022

EU/1/17/1221

Kisqali

Iceland

27.4.2022

EU/1/17/1221

Kisqali

Liechtenstein

30.4.2022

EU/1/17/1222

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan

Iceland

9.6.2022

EU/1/17/1222

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan

Liechtenstein

31.5.2022

EU/1/17/1223

Vosevi

Norway

20.5.2022

EU/1/17/1223

Vosevi

Liechtenstein

31.5.2022

EU/1/17/1224

Xermelo

Liechtenstein

30.6.2022

EU/1/17/1225

Symtuza

Norway

31.5.2022

EU/1/17/1225

Symtuza

Iceland

9.6.2022

EU/1/17/1225

Symtuza

Liechtenstein

31.5.2022

EU/1/17/1227

Entecavir Mylan

Liechtenstein

30.6.2022

EU/1/17/1250

Rubraca

Norway

24.3.2022

EU/1/17/1250

Rubraca

Iceland

16.3.2022

EU/1/17/1250

Rubraca

Liechtenstein

31.3.2022

EU/1/17/1262

Crysvita

Norway

11.2.2022

EU/1/17/1262

Crysvita

Iceland

25.1.2022

EU/1/17/1262

Crysvita

Liechtenstein

31.1.2022

EU/1/18/1345

Ondexxya

Norway

30.6.2022

EU/1/18/1345

Ondexxya

Iceland

17.5.2022

EU/1/18/1345

Ondexxya

Liechtenstein

30.4.2022

EU/1/19/1355

Lorviqua

Iceland

25.4.2022

EU/1/19/1355

Lorviqua

Liechtenstein

30.4.2022

EU/1/19/1360

Waylivra

Norway

24.2.2022

EU/1/19/1360

Waylivra

Iceland

21.2.2022

EU/1/19/1360

Waylivra

Liechtenstein

28.2.2022

EU/1/20/1437

Dovprela

Liechtenstein

30.6.2022

EU/1/20/1443

Zolgensma

Norway

31.5.2022

EU/1/20/1443

Zolgensma

Iceland

9.6.2022

EU/1/20/1443

Zolgensma

Liechtenstein

31.5.2022

EU/1/20/1446

Hepcludex

Liechtenstein

30.6.2022

EU/1/20/1459

Veklury

Norway

29.4.2022

EU/1/20/1459

Veklury

Iceland

4.5.2022

EU/1/20/1459

Veklury

Liechtenstein

30.4.2022

EU/1/20/1460

Rozlytrek

Liechtenstein

31.5.2022

EU/1/20/1474

BLENREP

Liechtenstein

30.6.2022

EU/1/20/1525

COVID- 19 Vaccine Janssen (JCOVDEN)

Norway

24.1.2022

EU/1/20/1525

COVID-19 Vaccine Janssen (JCOVDEN)

Iceland

14.2.2022

EU/1/20/1525

COVID-19 Vaccine Janssen (JCOVDEN)

Liechtenstein

31.1.2022

EU/1/20/1527

Retsevmo

Norway

26.1.2022

EU/1/20/1527

Retsevmo

Iceland

4.1.2022

EU/1/21/1535

Pemazyre

Norway

22.2.2022

EU/1/21/1535

Pemazyre

Iceland

23.2.2022

EU/1/21/1535

Pemazyre

Liechtenstein

28.2.2022

EU/1/21/1537

NEXPOVIO

Norway

2.6.2022

EU/1/21/1537

NEXPOVIO

Iceland

19.5.2022

EU/1/21/1537

NEXPOVIO

Liechtenstein

31.5.2022

EU/1/21/1538

Jemperli

Norway

22.2.2022

EU/1/21/1538

Jemperli

Iceland

22.2.2022

EU/1/21/1538

Jemperli

Liechtenstein

28.2.2022

EU/1/21/1539

Abecma

Liechtenstein

30.6.2022

EU/1/21/1552

Koselugo

Norway

12.5.2022

EU/1/21/1552

Koselugo

Liechtenstein

30.4.2022

EU/2/16/203

VarroMed

Norway

24.1.2022

EU/2/16/203

VarroMed

Iceland

21.1.2022

EU/2/16/203

VarroMed

Liechtenstein

31.1.2022

EU/2/17/205

Cytopoint

Norway

29.6.2022

EU/2/17/205

Cytopoint

Liechtenstein

30.4.2022

EU/2/17/206

Credelio

Norway

29.6.2022

EU/2/17/206

Credelio

Liechtenstein

30.4.2022

EU/2/17/207

Zulvac BTV

Norway

29.6.2022

EU/2/17/207

Zulvac BTV

Liechtenstein

30.4.2022

EU/2/17/209

RESPIPORC FLUpan H1N1

Norway

29.6.2022

EU/2/17/209

RESPIPORC FLUpan H1N1

Liechtenstein

30.4.2022

EU/2/17/210

Zeleris

Norway

30.6.2022

EU/2/17/210

Zeleris

Iceland

18.5.2022

EU/2/17/210

Zeleris

Liechtenstein

31.5.2022

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2022:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/05/320/005 | Noxafil | Liechtenstein | 31.1.2022 |
| EU/1/05/320/005 | Noxafil | Norway | 24.1.2022 |
| EU/1/05/320/005 | Noxafil | Iceland | 20.1.2022 |
| EU/1/05/324 | Naglazyme | Liechtenstein | 30.4.2022 |
| EU/1/13/837 | Tecfidera | Liechtenstein | 31.5.2022 |
| EU/1/14/930 | Jardiance | Liechtenstein | 31.3.2022 |
| EU/1/14/936/008 | Nuwiq | Liechtenstein | 31.1.2022 |
| EU/1/14/936/008 | Nuwiq | Norway | 24.1.2022 |
| EU/1/14/936/008 | Nuwiq | Iceland | 20.1.2022 |
| EU/1/15/1043/009-010 | Nucala | Liechtenstein | 30.4.2022 |
| EU/1/15/1043/009-010 | Nucala | Norway | 24.5.2022 |
| EU/1/15/1043/009-010 | Nucala | Iceland | 23.6.2022 |
| EU/1/16/1116/003-004 | Epclusa | Liechtenstein | 31.1.2022 |
| EU/1/16/1116/003-004 | Epclusa | Norway | 7.1.2022 |
| EU/1/16/1116/003-004 | Epclusa | Iceland | 18.1.2022 |
| EU/1/17/1217/004 | Nitisinone MDK | Iceland | 5.1.2022 |
| EU/1/17/1229/021-022 | Dupixent | Liechtenstein | 30.4.2022 |
| EU/1/17/1229/021 -022 | Dupixent | Iceland | 27.4.2022 |
| EU/1/17/1235/004-005 | Zejula | Liechtenstein | 31.5.2022 |
| EU/1/17/1235/004-005 | Zejula | Norway | 30.5.2022 |
| EU/1/17/1235/004-005 | Zejula | Iceland | 10.6.2022 |
| EU/1/17/1247/015-016 | Adynovi | Liechtenstein | 31.1.2022 |
| EU/1/17/1247/015-016 | Adynovi | Norway | 14.1.2022 |
| EU/1/17/1247/015-016 | Adynovi | Iceland | 20.1.2022 |
| EU/1/17/1251/010-011 | Ozempic | Liechtenstein | 31.1.2022 |
| EU/1/17/1251/010-011 | Ozempic | Norway | 11.1.2022 |
| EU/1/17/1251/010-011 | Ozempic | Iceland | 20.1.2022 |
| EU/1/18/1274/006-008 | Trydonis | Liechtenstein | 31.1.2022 |
| EU/1/18/1274/006-008 | Trydonis | Norway | 24.1.2022 |
| EU/1/18/1274/006-008 | Trydonis | Iceland | 21.1.2022 |
| EU/1/18/1323/003 | Ilumetri | Liechtenstein | 30.4.2022 |
| EU/1/18/1323/003 | Ilumetri | Norway | 20.5.2022 |
| EU/1/18/1323/003 | Ilumetri | Iceland | 28.6.2022 |
| EU/1/19/1414/007-008 | Mayzent | Liechtenstein | 28.2.2022 |
| EU/1/19/1414/007-008 | Mayzent | Norway | 16.2.2022 |
| EU/1/19/1414/007-008 | Mayzent | Iceland | 24.2.2022 |
| EU/1/20/1422/016-017 | Lyumjev | Liechtenstein | 30.4.2022 |
| EU/1/20/1422/016-017 | Lyumjev | Norway | 18.5.2022 |
| EU/1/20/1422/016-017 | Lyumjev | Iceland | 17.5.2022 |
| EU/1/20/1468/002 | Kaftrio | Liechtenstein | 31.1.2022 |
| EU/1/20/1468/002 | Kaftrio | Norway | 7.1.2022 |
| EU/1/20/1468/002 | Kaftrio | Iceland | 19.1.2022 |
| EU/1/20/1473/004-005 | AYVAKYT | Liechtenstein | 31.3.2022 |
| EU/1/20/1473/004-005 | AYVAKYT | Norway | 31.3.2022 |
| EU/1/20/1473/004-005 | AYVAKYT | Iceland | 19.4.2022 |
| EU/1/20/1500/003-004 | Xofluza | Liechtenstein | 30.4.2022 |
| EU/1/20/1500/003-004 | Xofluza | Norway | 29.4.2022 |
| EU/1/20/1501/003-004 | Sogroya | Liechtenstein | 30.4.2022 |
| EU/1/20/1501/003-004 | Sogroya | Norway | 29.4.2022 |
| EU/1/20/1501/003-004 | Sogroya | Iceland | 12.5.2022 |
| EU/1/20/1513/013-016 | Yuflyma | Liechtenstein | 28.2.2022 |
| EU/1/20/1513/013-016 | Yuflyma | Norway | 16.2.2022 |
| EU/1/20/1513/013-016 | Yuflyma | Iceland | 15.3.2022 |
| EU/2/13/154/028-033 | Apoquel | Norway | 5.1.2022 |

EU-Number

Product

Country

Date of authorisation

EU/1/05/320/005

Noxafil

Liechtenstein

31.1.2022

EU/1/05/320/005

Noxafil

Norway

24.1.2022

EU/1/05/320/005

Noxafil

Iceland

20.1.2022

EU/1/05/324

Naglazyme

Liechtenstein

30.4.2022

EU/1/13/837

Tecfidera

Liechtenstein

31.5.2022

EU/1/14/930

Jardiance

Liechtenstein

31.3.2022

EU/1/14/936/008

Nuwiq

Liechtenstein

31.1.2022

EU/1/14/936/008

Nuwiq

Norway

24.1.2022

EU/1/14/936/008

Nuwiq

Iceland

20.1.2022

EU/1/15/1043/009-010

Nucala

Liechtenstein

30.4.2022

EU/1/15/1043/009-010

Nucala

Norway

24.5.2022

EU/1/15/1043/009-010

Nucala

Iceland

23.6.2022

EU/1/16/1116/003-004

Epclusa

Liechtenstein

31.1.2022

EU/1/16/1116/003-004

Epclusa

Norway

7.1.2022

EU/1/16/1116/003-004

Epclusa

Iceland

18.1.2022

EU/1/17/1217/004

Nitisinone MDK

Iceland

5.1.2022

EU/1/17/1229/021-022

Dupixent

Liechtenstein

30.4.2022

EU/1/17/1229/021 -022

Dupixent

Iceland

27.4.2022

EU/1/17/1235/004-005

Zejula

Liechtenstein

31.5.2022

EU/1/17/1235/004-005

Zejula

Norway

30.5.2022

EU/1/17/1235/004-005

Zejula

Iceland

10.6.2022

EU/1/17/1247/015-016

Adynovi

Liechtenstein

31.1.2022

EU/1/17/1247/015-016

Adynovi

Norway

14.1.2022

EU/1/17/1247/015-016

Adynovi

Iceland

20.1.2022

EU/1/17/1251/010-011

Ozempic

Liechtenstein

31.1.2022

EU/1/17/1251/010-011

Ozempic

Norway

11.1.2022

EU/1/17/1251/010-011

Ozempic

Iceland

20.1.2022

EU/1/18/1274/006-008

Trydonis

Liechtenstein

31.1.2022

EU/1/18/1274/006-008

Trydonis

Norway

24.1.2022

EU/1/18/1274/006-008

Trydonis

Iceland

21.1.2022

EU/1/18/1323/003

Ilumetri

Liechtenstein

30.4.2022

EU/1/18/1323/003

Ilumetri

Norway

20.5.2022

EU/1/18/1323/003

Ilumetri

Iceland

28.6.2022

EU/1/19/1414/007-008

Mayzent

Liechtenstein

28.2.2022

EU/1/19/1414/007-008

Mayzent

Norway

16.2.2022

EU/1/19/1414/007-008

Mayzent

Iceland

24.2.2022

EU/1/20/1422/016-017

Lyumjev

Liechtenstein

30.4.2022

EU/1/20/1422/016-017

Lyumjev

Norway

18.5.2022

EU/1/20/1422/016-017

Lyumjev

Iceland

17.5.2022

EU/1/20/1468/002

Kaftrio

Liechtenstein

31.1.2022

EU/1/20/1468/002

Kaftrio

Norway

7.1.2022

EU/1/20/1468/002

Kaftrio

Iceland

19.1.2022

EU/1/20/1473/004-005

AYVAKYT

Liechtenstein

31.3.2022

EU/1/20/1473/004-005

AYVAKYT

Norway

31.3.2022

EU/1/20/1473/004-005

AYVAKYT

Iceland

19.4.2022

EU/1/20/1500/003-004

Xofluza

Liechtenstein

30.4.2022

EU/1/20/1500/003-004

Xofluza

Norway

29.4.2022

EU/1/20/1501/003-004

Sogroya

Liechtenstein

30.4.2022

EU/1/20/1501/003-004

Sogroya

Norway

29.4.2022

EU/1/20/1501/003-004

Sogroya

Iceland

12.5.2022

EU/1/20/1513/013-016

Yuflyma

Liechtenstein

28.2.2022

EU/1/20/1513/013-016

Yuflyma

Norway

16.2.2022

EU/1/20/1513/013-016

Yuflyma

Iceland

15.3.2022

EU/2/13/154/028-033

Apoquel

Norway

5.1.2022

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2022:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/01/174 | Starlix | Norway | 16.6.2022 |
| EU/1/01/174 | Starlix | Liechtenstein | 30.4.2022 |
| EU/1/03/249 | Vivanza | Norway | 1.3.2022 |
| EU/1/03/249 | Vivanza | Iceland | 10.2.2022 |
| EU/1/03/249 | Vivanza | Liechtenstein | 28.2.2022 |
| EU/1/03/250 | Ytracis | Norway | 22.2.2022 |
| EU/1/03/250 | Ytracis | Iceland | 5.1.2022 |
| EU/1/07/384 | Docetaxel Zentiva | Liechtenstein | 31.5.2022 |
| EU/1/07/384 | Docetaxel Zentiva | Iceland | 10.6.2022 |
| EU/1/07/421 | Glubrava | Norway | 8.6.2022 |
| EU/1/07/421 | Glubrava | Liechtenstein | 31.5.2022 |
| EU/1/08/491 | Rasilez HCT | Norway | 22.2.2022 |
| EU/1/08/491 | Rasilez HCT | Iceland | 11.1.2022 |
| EU/1/09/519 | PANTOLOC Control | Norway | 10.1.2022 |
| EU/1/09/519 | PANTOLOC Control | Iceland | 5.1.2022 |
| EU/1/11/695 | Leganto | Norway | 18.1.2022 |
| EU/1/11/695 | Leganto | Iceland | 5.1.2022 |
| EU/1/11/695 | Leganto | Liechtenstein | 31.1.2022 |
| EU/1/11/728 | Pramipexole Accord | Norway | 22.4.2022 |
| EU/1/11/728 | Pramipexole Accord | Iceland | 4.5.2022 |
| EU/1/11/728 | Pramipexole Accord | Liechtenstein | 30.4.2022 |
| EU/1/13/825 | Imatinib Actavis | Liechtenstein | 31.5.2022 |
| EU/1/15/1034 | Pemetrexed Lilly | Norway | 23.3.2022 |
| EU/1/15/1034 | Pemetrexed Lilly | Iceland | 21.1.2022 |
| EU/1/15/1034 | Pemetrexed Lilly | Liechtenstein | 31.3.2022 |
| EU/1/15/1069 | Episalvan | Iceland | 16.6.2022 |
| EU/1/15/1069 | Episalvan | Liechtenstein | 30.6.2022 |
| EU/1/16/1131 | Thorinane | Norway | 4.3.2022 |
| EU/1/16/1131 | Thorinane | Liechtenstein | 31.3.2022 |
| EU/1/17/1183 | Pemetrexed Pfizer | Norway | 23.3.2022 |
| EU/1/17/1183 | Pemetrexed Pfizer | Iceland | 27.1.2022 |
| EU/1/17/1183 | Pemetrexed Pfizer | Liechtenstein | 31.1.2022 |
| EU/1/19/1363 | Zynquista | Norway | 21.4.2022 |
| EU/1/19/1363 | Zynquista | Iceland | 6.4.2022 |
| EU/1/19/1363 | Zynquista | Liechtenstein | 31.3.2022 |
| EU/1/19/1367 | Zynteglo | Norway | 21.4.2022 |
| EU/1/19/1367 | Zynteglo | Iceland | 20.4.2022 |
| EU/1/19/1367 | Zynteglo | Liechtenstein | 31.3.2022 |
| EU/1/19/1387 | Senstend | Liechtenstein | 30.6.2022 |
| EU/1/19/1421 | Staquis | Norway | 9.2.2022 |
| EU/1/19/1421 | Staquis | Iceland | 10.2.2022 |
| EU/1/19/1421 | Staquis | Liechtenstein | 31.1.2022 |
| EU/2/14/180 | Coliprotec F4 | Norway | 22.2.2022 |

EU-Number

Product

Country

Date of withdrawal

EU/1/01/174

Starlix

Norway

16.6.2022

EU/1/01/174

Starlix

Liechtenstein

30.4.2022

EU/1/03/249

Vivanza

Norway

1.3.2022

EU/1/03/249

Vivanza

Iceland

10.2.2022

EU/1/03/249

Vivanza

Liechtenstein

28.2.2022

EU/1/03/250

Ytracis

Norway

22.2.2022

EU/1/03/250

Ytracis

Iceland

5.1.2022

EU/1/07/384

Docetaxel Zentiva

Liechtenstein

31.5.2022

EU/1/07/384

Docetaxel Zentiva

Iceland

10.6.2022

EU/1/07/421

Glubrava

Norway

8.6.2022

EU/1/07/421

Glubrava

Liechtenstein

31.5.2022

EU/1/08/491

Rasilez HCT

Norway

22.2.2022

EU/1/08/491

Rasilez HCT

Iceland

11.1.2022

EU/1/09/519

PANTOLOC Control

Norway

10.1.2022

EU/1/09/519

PANTOLOC Control

Iceland

5.1.2022

EU/1/11/695

Leganto

Norway

18.1.2022

EU/1/11/695

Leganto

Iceland

5.1.2022

EU/1/11/695

Leganto

Liechtenstein

31.1.2022

EU/1/11/728

Pramipexole Accord

Norway

22.4.2022

EU/1/11/728

Pramipexole Accord

Iceland

4.5.2022

EU/1/11/728

Pramipexole Accord

Liechtenstein

30.4.2022

EU/1/13/825

Imatinib Actavis

Liechtenstein

31.5.2022

EU/1/15/1034

Pemetrexed Lilly

Norway

23.3.2022

EU/1/15/1034

Pemetrexed Lilly

Iceland

21.1.2022

EU/1/15/1034

Pemetrexed Lilly

Liechtenstein

31.3.2022

EU/1/15/1069

Episalvan

Iceland

16.6.2022

EU/1/15/1069

Episalvan

Liechtenstein

30.6.2022

EU/1/16/1131

Thorinane

Norway

4.3.2022

EU/1/16/1131

Thorinane

Liechtenstein

31.3.2022

EU/1/17/1183

Pemetrexed Pfizer

Norway

23.3.2022

EU/1/17/1183

Pemetrexed Pfizer

Iceland

27.1.2022

EU/1/17/1183

Pemetrexed Pfizer

Liechtenstein

31.1.2022

EU/1/19/1363

Zynquista

Norway

21.4.2022

EU/1/19/1363

Zynquista

Iceland

6.4.2022

EU/1/19/1363

Zynquista

Liechtenstein

31.3.2022

EU/1/19/1367

Zynteglo

Norway

21.4.2022

EU/1/19/1367

Zynteglo

Iceland

20.4.2022

EU/1/19/1367

Zynteglo

Liechtenstein

31.3.2022

EU/1/19/1387

Senstend

Liechtenstein

30.6.2022

EU/1/19/1421

Staquis

Norway

9.2.2022

EU/1/19/1421

Staquis

Iceland

10.2.2022

EU/1/19/1421

Staquis

Liechtenstein

31.1.2022

EU/2/14/180

Coliprotec F4

Norway

22.2.2022

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2022:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| | | | |

EU-Number

Product

Country

Date of suspension

---